Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research.

Automated summary

Viral diseases pose a significant threat to public health and can lead to global pandemics. Antiviral antibody therapeutics have emerged as valuable options for prevention and treatment, both alone and in combination with other therapies. This article discusses the unique biochemical and physiological properties of polyclonal and monoclonal antiviral antibodies that make them effective as therapeutic agents. It also explores methods of antibody characterization and potency assessment, compares polyclonal and monoclonal products, and examines the benefits and challenges of combining antiviral antibodies with other therapeutics. Additionally, novel approaches to the development and characterization of antiviral antibodies are discussed, along with areas that require further research.